Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · IEX Real-Time Price · USD
-0.25 (-2.44%)
At close: May 24, 2024, 4:00 PM
+0.02 (0.20%)
After-hours: May 24, 2024, 7:59 PM EDT

Company Description

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.

The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.

It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers.

The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H.

Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH.

The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017.

Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics logo
Country United States
Founded 2007
Industry Biotechnology
Sector Healthcare
Employees 557
CEO Dr. Frederick G. Vogt Esq., J.D., Ph.D.

Contact Details

825 Industrial Road, 4th Floor
San Carlos, California 94070
United States
Phone (650) 260-7120

Stock Details

Ticker Symbol IOVA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001425205
CUSIP Number 462260100
ISIN Number US4622601007
Employer ID 75-3254381
SIC Code 2836

Key Executives

Name Position
Dr. Frederick G. Vogt Esq., J.D., Ph.D. Interim Chief Executive Officer, President, General Counsel and Corporate Secretary
Jean-Marc Bellemin M.B.A. Chief Financial Officer, Principal Accounting Officer and Treasurer
Dr. Igor P. Bilinsky Chief Operating Officer
Dr. Friedrich Graf Finckenstein M.D. Chief Medical Officer
Sara Pellegrino Vice President of Investor Relations and Public Relations
Tracy Winton Senior Vice President of Human Resources
Howard B. Johnson M.B.A. Chief Business Officer
James Ziegler M.B.A. Executive Vice President of Commercial
Dr. Raj K. Puri M.D., Ph.D. Executive Vice President of Regulatory Strategy and Translational Medicine
Brian Shew M.B.A. Senior Vice President and Head of Digital and Information Technology

Latest SEC Filings

Date Type Title
May 24, 2024 8-K Current Report
May 17, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 10, 2024 S-8 Securities to be offered to employees in employee benefit plans
May 9, 2024 10-Q Quarterly Report
May 9, 2024 8-K Current Report
May 1, 2024 ARS Filing
Apr 29, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2024 DEF 14A Other definitive proxy statements
Apr 3, 2024 8-K Current Report
Mar 29, 2024 8-K Current Report